COST-EFFECTIVENESS OF HIGH VERSUS LOW DOSE ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIs) IN THE TREATMENT OF CHRONIC HEART FAILURE (CHF)- AN ECONOMIC ANALYSIS OF THE US ASSESSMENT OF TREATMENT WITH LISINOPRIL AND SURVIVAL (ATLAS) TRIAL
Author(s)
Schwartz JS1, Wang Y2, Cleland J3, ATLAS Investigators, 1University of Pennsylvania, Philadelphia, PA, USA; 2AstraZeneca Pharmaceuticals, Wilmington, DE, USA; 3University of Kull, Cottingham, UK
ACEIs reduce CHF mortality and hospitalization. However, commonly prescribed doses are often much lower than target doses used in randomized clinical trials (RCTs) and recommended by evidence-based practice guidelines. In ATLAS, a RCT of high (32.5-35mg) versus low (2.5-5mg) dose lisinopril in 3,164 class II-IV CHF patients with left ventricular ejection fraction
Conference/Value in Health Info
2000-05, ISPOR 2000, Arlington, VA, USA
Value in Health, Vol. 3, No. 2 (March/April 2000)
Code
BT4
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders